<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875534</url>
  </required_header>
  <id_info>
    <org_study_id>TCC-NHS-01</org_study_id>
    <nct_id>NCT03875534</nct_id>
  </id_info>
  <brief_title>A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia</brief_title>
  <official_title>ACHieve: A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascendis Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascendis Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term, multi-center, longitudinal, observational study in children with
      achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with
      ACH. This is a natural history study and no study medication will be administered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized height velocity (centimeters/year) in children with achondroplasia</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Subjects will undergo a series of height measurements (in centimeters) on Day 1 and then every 6 months over the study period with height velocity reported in cm/year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of natural history of achondroplasia symptoms in children with achondroplasia</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>To characterize achondroplasia symptoms in children with achondroplasia</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Achondroplasia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Infants and children with achondroplasia from birth to 8 years of age.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Legally authorized representative is willing and able to provide written, signed
             informed consent (with a written assent from the child when appropriate per local
             requirements)

          2. Willing and able to comply with study protocol per investigator judgement

          3. Clinical diagnosis of achondroplasia (confirmed by the investigator)

          4. Age between 0 to 8 years old at enrollment

          5. Able to stand without assistance (if the child is 24 months or older)

        Exclusion Criteria:

          1. Have received chronic treatment (&gt; 3 months) of human growth hormone (hGH) or other
             medicinal products intended to affect stature or body proportionality at any time

          2. Have received any dose of medicinal products intended to affect stature or body
             proportionality within the previous 6 months of screening

          3. Have received any investigational medicinal product or device intended to affect
             stature or body proportionality at any time

          4. History or presence of injury or disease of the growth plate(s), other than ACH, that
             affects growth potential of long bones

          5. History of any bone-related surgery that affects growth potential of long bones, such
             as orthopedic reconstructive surgery and osteotomy (foramen magnum decompression, and
             laminectomy with full recovery are allowed with minimum of 6 months of bone healing.
             Limb-lengthening with full recovery is allowed with a minimum of 12 months of bone
             healing.)

          6. Have forms of skeletal dysplasias other than achondroplasia or medical conditions that
             result in short stature or abnormal bone growth [such as severe achondroplasia with
             developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth
             hormone deficiency, Turner syndrome, pseudoachondroplasia. uncontrolled
             hypothyroidism, uncontrolled diabetes mellitus, autoimmune disease requiring
             corticosteroid therapy, inflammatory bowel disease, and chronic renal insufficiency]

          7. History or presence of malignant disease, other than basal cell epithelioma/carcinoma
             or completely resected squamous skin cancer with no recurrence for 12 months per
             medical records
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Charlton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ascendis Pharma A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Affairs Director</last_name>
    <phone>+1 855-795-2467</phone>
    <phone_ext>4420</phone_ext>
    <email>achieve-study@ascendispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G-1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Montr√©al</city>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>LA12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Achondroplasia</keyword>
  <keyword>Dwarfism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

